Navigation Links
IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
Date:10/3/2007

Former Procter & Gamble security executive has agreed to work with

IntegriChain to enhance the company's Market Vigilance(TM) Survey

Program(TM).

PRINCETON, N.J., Oct. 3 /PRNewswire/ -- IntegriChain, Inc. the leading provider of analytic services to maximize channel integrity and create business value for pharmaceutical, biotech, and medical device companies, today announces the agreement with Ed Casey and Associates to manage their Market Vigilance Survey Program(TM). Mr. Casey brings a depth of pharmaceutical domain expertise, corporate security and law enforcement leadership experience spanning more than 34 years.

Mr. Casey retired as the Director of Global Security for the Procter & Gamble Company after a 20 year career. Prior to P&G, he served for 14 years as a Special Agent with the U.S. Treasury Department where he concentrated on white-collar crime investigations. Mr. Casey holds memberships in a variety of security organizations including; American Society for Industrial Security (ASIS), International Security Management Association (ISMA) and the Chief Security Officers Executive Council's Board of Advisors of which he is a founding member.

Market Vigilance Survey Program utilizes IntegriChain's channel analytics capabilities to identify possible U.S. outlets including hospitals, clinics, long term care facilities and other NGOs that are possibly diverting or facilitating the movement of counterfeit product in the U.S. supply chain. Once identified as an at-risk outlet, the Survey Program can solicit and purchase product to ensure the efficacy of the product provided. IntegriChain's service has been used successfully by several large pharmaceutical manufacturers to identify and purchase illegal or illicit product from a host of U.S. wholesalers, long term care facilities, hospitals, retail outlets and other NGOs.

"The integrity of the pharmaceutical value chain is being challenged every day. The IntegriChain solutions are well positioned to identify and quantify the level of risk for our customers," said Casey. "I'm pleased to work with IntegriChain team to deliver high-value solutions for the industry."

"IntegriChain is working with 11 of the top 20 U.S. pharmaceutical manufacturers across a broad range of channel integrity analytics, including 'safe and secure' initiatives, demand data validation, and EDI data integration and quality assurance," states Kevin Leininger, chief executive officer of IntegriChain. "We are excited to welcome Ed and look forward to his experience, leadership and acceleration of this valuable service to the pharmaceutical industry."

About IntegriChain, Inc.

IntegriChain is the premier provider of supply chain visibility and integrity solutions to the healthcare industry. Leading manufacturers employ IntegriChain's proprietary data enrichment and analytic services to increase supply chain transparency and accountability. Managed markets, sales operations, supply chain and product protection managers leverage IntegriChain to reduce diversion and importation, prevent stock-outs, and maximize sales and marketing responsiveness throughout the product life cycle. Manufacturers utilize IntegriChain to monitor more than $35 billion of pharmaceutical trade, achieving measurable returns in added revenue and enhanced brand integrity. For more information visit the company's website at http://www.integrichain.com


'/>"/>
SOURCE IntegriChain, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supercomputer Grid Enlists PCs To Combat AIDS
2. Nova Scotia MP, Bill Casey, indebted to Cadman clinic
3. A Carrier Protein Associates With Human Insulin Resistance
4. Sleepy drivers increase road death toll
5. Traffic Violations Result in Safer Drivers
6. Dyslexia may slow a drivers reaction time as much as moderate drinking!!
7. Study suggests symptom driven therapy for adults with asthma
8. Peppermint or cinnamon smell can make drivers more alert
9. Mechanical forces drive early heart development
10. Measles Vaccination Drive Intensified In Quake-Hit Pakistan
11. More Funds Are Required For Immunisation Drive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery ... Kevin Sadati, is pleased to announce a new treatment option called Vivace Microneedling. ... their face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are ... dentist practicing in Mt. Pleasant, SC, with or without a referral. A full mouth ... with missing teeth in Charleston, SC. Those who suffer from gum disease, ...
(Date:5/23/2017)... WI (PRWEB) , ... May 23, 2017 , ... Patients ... to call Dr. Angela Cotey’s practice to schedule an appointment, with or without a ... and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative to a ...
(Date:5/22/2017)... PA (PRWEB) , ... May 22, 2017 , ... An ... to write with a pen. "My wife’s hand was damaged in a firework accident, ... something that helps people with manual problems." , He then designed and created a ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... larger group investing in InsightRX, an early stage company in San Francisco that ... pharmacological characteristics. Greatpoint Ventures Innovation Fund acted as the lead investor ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology: